(Total Views: 880)
Posted On: 06/12/2024 1:25:38 PM
Post# of 148870
Quote:
which should mean that if leronlimab has similar efficacy and far less - all the way to zero - side effects, it HAS to be approved?
Similar efficacy is to low of a bar for leronlimab. We know what lesser drugs for CCR5 blockade have shown in Alzheimer's. We know a lot of what CCR5 blockade does overall. There is no way that leronlimab doesn't far surpass any approved drug out there.
(20)
(0)Scroll down for more posts ▼
